CA Patent

CA3223247A1 — Sodium n-(8-(2- hydroxybenzoyl)amino)caprylate polymorphic form a

Assigned to Novo Nordisk AS · Expires 2023-01-19 · 3y expired

What this patent protects

The present invention relates to a method of making sodium N-(8-2-Hydroxybenzoyl)amino caprylate form A, SNAC polymorphic form A having improved stability and the use of said SNAC polymorphic form A in a solid pharmaceutical dosage form-

USPTO Abstract

The present invention relates to a method of making sodium N-(8-2-Hydroxybenzoyl)amino caprylate form A, SNAC polymorphic form A having improved stability and the use of said SNAC polymorphic form A in a solid pharmaceutical dosage form-

Drugs covered by this patent

Patent Metadata

Patent number
CA3223247A1
Jurisdiction
CA
Classification
—
Expires
2023-01-19
Drug substance claim
No
Drug product claim
No
Assignee
Novo Nordisk AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.